Description
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC).
Cat.No
A543
Name
Tiragolumab
Chemical Properties
CAS
1918185-84-8
Synonyms
RO 7092284;RG 6058;MTIG 7192A;Tiragolumab;Research Grade Tiragolumab(DHH72401);Tiragolumab (anti-TIGIT);RO 7092284|||RG6058-10|||MTIG-7192A|||RG6058-11|||RG-6058
pH value
Corresponds to reference standard: PASS
Non-reduced CE-SDS
>95%
SEC-HPLC
>95%
Isoelectric Point
Corresponds to reference standard
Bacterial Endotoxins Test
Residual Proteins of Host Cell
Exogenous Residual DNA
Residual protein A
Biological Activity
Osmolality
Corresponds to reference standard: PASS
Peptide mapping
Corresponds to reference standard: PASS
N-terminal sequence
Corresponds to reference standard: PASS
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
Tel: +86-21-58447131Fax: +86-21-61642470Email:
Website:
